GlassScriptPhysician profile
Kaiser Toosy
NPI 1215143953
$4,679.10
in general payments reported to CMS, 2019-2025
16 companies · $1,439 in 2025
The $1,439 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $548 · 2021: $482 · 2022: $406 · 2023: $576 · 2024: $629 · 2025: $1,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553 · Education: $92.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.61 |
| Education | $92.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,985.83 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $554.17 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Amgen INC. | $392.17 | 2022-2025 | Tezspire |
| Philips North America LLC | $207.87 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $89.65 | 2025 | Glassia |
| Genzyme Corporation | $85.42 | 2025 | |
| Insmed, INC. | $78.68 | 2025 | Arikayce |
| Verona Pharma, INC. | $62.03 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.25 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $42.02 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $32.63 | 2025 | |
| Csl Behring | $27.30 | 2020 | |
| Merck Sharp & Dohme LLC | $27.18 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $18.51 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $12.63 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaiser Toosy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.